50 Participants Needed

TMS for Smoking Cessation in Schizophrenia

Recruiting at 1 trial location
DD
XD
KT
VA
Overseen ByVictoria Acosta
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: The University of Texas Health Science Center, Houston
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to help individuals with schizophrenia quit smoking. It uses repetitive transcranial magnetic stimulation (rTMS), which involves magnets to stimulate brain areas, to determine if it can reduce smoking and alter brain activity. The trial includes two groups, each receiving different rTMS treatments. It seeks participants who have smoked at least five cigarettes daily for the past month and have a schizophrenia spectrum disorder diagnosis. As an unphased trial, participants can contribute to groundbreaking research that may lead to new treatment options.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are taking more than 400 mg of clozapine per day, you may not be eligible to participate.

What prior data suggests that this rTMS technique is safe for smoking cessation in schizophrenia?

Research has shown that repetitive transcranial magnetic stimulation (rTMS) is generally safe for people, including those with schizophrenia. Studies indicate that both the F8 coil and the H-coil are well-tolerated.

The F8 coil has a strong safety record. It has been used safely to treat major depressive disorder and is approved in Canada for short-term assistance with quitting smoking, with serious side effects being rare.

The H-coil is also considered safe and has received FDA approval for treating major depression and obsessive-compulsive disorder. Research suggests that even for individuals with schizophrenia, rTMS does not increase the risk of serious side effects, such as seizures.

Overall, both rTMS methods appear to be safe options, with few reported complications.12345

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for smoking cessation in schizophrenia because they use a technique called repetitive transcranial magnetic stimulation (rTMS). Unlike traditional methods such as nicotine replacement therapy or behavioral counseling, rTMS targets specific brain circuits involved in addiction. The use of different coils, F8-coil and H-coil, allows for precise delivery of magnetic pulses to stimulate the brain, potentially offering a new way to reduce smoking cravings. This innovative approach could provide a non-invasive, medication-free option for individuals with schizophrenia who struggle with smoking addiction.

What evidence suggests that this trial's treatments could be effective for smoking cessation in schizophrenia?

Research suggests that repetitive transcranial magnetic stimulation (rTMS) might help people with schizophrenia quit smoking. Studies have found that rTMS can reduce nicotine cravings and dependence in these individuals. In this trial, participants will receive either F8-coil rTMS or H-coil rTMS. Both F8-coil and H-coil rTMS have been linked to reduced smoking and fewer cravings. Some participants reported mild headaches as side effects, but these were generally rare. Overall, rTMS shows promise as a method to help those with schizophrenia reduce smoking.26789

Who Is on the Research Team?

XD

Xiaoming Du, PhD

Principal Investigator

The University of Texas Health Science Center, Houston

Are You a Good Fit for This Trial?

This trial is for adults aged 18-60 who smoke at least 5 cigarettes daily for the past year, have schizophrenia spectrum disorder, and can consent to participate. Excluded are those with certain metal implants, severe head injuries, pregnancy or unprotected sex without birth control recently, active suicidal thoughts or behaviors, recent substance abuse (except nicotine/marijuana), specific medication dosages or medical conditions affecting brain function.

Inclusion Criteria

I am between 22 and 65 years old.
Ability to give written informed consent
Smoking in the last one year or more and average cigarette per day ≥ 5 in the past 4 weeks
See 7 more

Exclusion Criteria

Lives 30+ miles from UTHealth Houston
I have a condition that increases my risk of seizures.
I have had a head injury with unconsciousness for over 10 minutes or brain surgery.
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive active rTMS from F8 coil or H coil for smoking cessation

4 weeks
Weekly visits for rTMS sessions

Follow-up

Participants are monitored for changes in smoking behavior and brain connectivity

4 weeks
2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Circuitry-Guided Smoking Cessation in Schizophrenia
  • rTMS with F8-coil
  • rTMS with H-coil
Trial Overview The study tests two types of rTMS treatments using F8-coil and H-coil on patients with schizophrenia for smoking cessation. It measures changes in smoking behavior and brain connectivity before treatment, during different stages of rTMS therapy, and at follow-up sessions.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Study groupExperimental Treatment1 Intervention
Group II: Active control groupActive Control1 Intervention

Circuitry-Guided Smoking Cessation in Schizophrenia is already approved in United States for the following indications:

🇺🇸
Approved in United States as rTMS for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

The University of Texas Health Science Center, Houston

Lead Sponsor

Trials
974
Recruited
361,000+

University of Maryland, Baltimore

Lead Sponsor

Trials
729
Recruited
540,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+

Published Research Related to This Trial

In a study involving 13 smokers with schizophrenia and 14 non-psychiatric controls, high-frequency repetitive transcranial magnetic stimulation (rTMS) did not significantly reduce tobacco craving or improve cognitive function after a short-term treatment period.
Despite the lack of efficacy in modifying craving and cognitive outcomes, the study found that rTMS was safe, with no significant adverse events reported, suggesting that further long-term studies are needed to explore its potential benefits.
Effects of short-term, high-frequency repetitive transcranial magnetic stimulation to bilateral dorsolateral prefrontal cortex on smoking behavior and cognition in patients with schizophrenia and non-psychiatric controls.Kozak, K., Sharif-Razi, M., Morozova, M., et al.[2021]
In a study involving 35 male schizophrenia patients, high-frequency rTMS (10Hz) over the left dorsolateral prefrontal cortex significantly reduced cigarette consumption compared to a sham treatment, with effects observed as early as the first week of stimulation.
The treatment did not correlate with changes in negative or depressive symptoms of schizophrenia, suggesting that rTMS specifically targets smoking behavior rather than overall psychiatric symptoms.
Repetitive transcranial magnetic stimulation reduces cigarette consumption in schizophrenia patients.Prikryl, R., Ustohal, L., Kucerova, HP., et al.[2017]
A multicenter double-blind RCT involving 262 chronic smokers showed that repetitive transcranial magnetic stimulation (rTMS) significantly increased the continuous quit rate (CQR) to 19.4% compared to 8.7% for the sham treatment, indicating its efficacy in promoting smoking cessation.
This study established a safe treatment protocol for rTMS, which has now received FDA clearance as an aid for smoking cessation, marking a significant advancement in addiction medicine.
Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial.Zangen, A., Moshe, H., Martinez, D., et al.[2021]

Citations

Repetitive transcranial magnetic stimulation for smoking ...A proof-of-concept study has shown its potential for use in patients with schizophrenia, but large trials designed to determine smoking ...
Effect of Repetitive Transcranial Magnetic Stimulation ...Schizophrenia is a chronic mental illness that affects approximately 21 million people worldwide (1). It is marked by positive symptoms, such as hallucinations ...
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)If the corresponding brain circuits were successfully modulated, the treatment efficacy will be significantly improved and schizophrenia patients will benefit ...
4.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/40472574/
Effectiveness and safety of repeated transcranial magnetic ...People with schizophrenia were more likely to reduce smoking and nicotine dependence. Adverse reactions were mild, with only the incidence of headache being ...
Efficacy of repetitive transcranial magnetic stimulation for ...... outcomes including nicotine dependence ... stimulation to test alternative causal pathways for nicotine addiction in schizophrenia.
Consensus review and considerations on TMS to treat ...Safety of rTMS. Repetitive transcranial magnetic stimulation (rTMS) for the treatment of MDD has a generally favorable safety and tolerability profile. The most ...
Clinical Practice Guidelines for the Therapeutic Use of ...One such newer treatment is the use of repetitive transcranial magnetic stimulation (rTMS). rTMS is a non-invasive, non-convulsive method of brain stimulation ...
Clinical efficacy of deep transcranial magnetic stimulation ...The H-coil configuration received clearance from FDA for the treatment of major depression (H1-coil), obsessive-compulsive disorder (H7-coil), smoking cessation ...
TMS for Smoking Cessation in SchizophreniaResearch shows that repetitive transcranial magnetic stimulation (rTMS) is generally safe for humans, including those with schizophrenia and other conditions.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security